Evidence map›Paper›PMID 35324426›Full record

ArticleeLife2022

Remodeling of dermal adipose tissue alleviates cutaneous toxicity induced by anti-EGFR therapy.

Leying Chen, Qing You, Min Liu, Shuaihu Li, Zhaoyu Wu, Jiajun Hu, Yurui Ma, Liangyong Xia, Ying Zhou, Nan Xu and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Leying Chen *School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-6448-4177
Qing You *School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Min LiuSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Shuaihu LiSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-2049-7304
Zhaoyu WuSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Jiajun HuSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Yurui MaSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Liangyong XiaSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Ying ZhouSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Nan XuDepartment of Dermatology, Shanghai East Hospital, Tongji University, Shanghai, China.
Shiyi ZhangSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-9375-5992
Shanghai Jiao Tong University · CNShanghai East Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-epidermal growth factor receptor (EGFR) therapy-associated cutaneous toxicity is a syndrome characterized by papulopustular rash, local inflammation, folliculitis, and microbial infection, resulting in a decrease in quality of life and dose interruption. However, no effective clinical intervention is available for this adverse effect. Here, we report the atrophy of dermal white adipose tissue (dWAT), a highly plastic adipose tissue with various skin-specific functions, correlates with rash occurrence and exacerbation in a murine model of EGFR inhibitor-induced rash. The reduction in dWAT is due to the inhibition of adipogenic differentiation by defects in peroxisome proliferator-activated receptor γ (PPARγ) signaling, and increased lipolysis by the induced expression of the lipolytic cytokine IL6. The activation of PPARγ by rosiglitazone maintains adipogenic differentiation and represses the transcription of IL6, eventually improving skin functions and ameliorating the severity of rash without altering the antitumor effects. Thus, activation of PPARγ represents a promising approach to ameliorate cutaneous toxicity in patients with cancer who receive anti-EGFR therapy.

Indexed as

ExanthemaPPAR gammaAdipose TissueAnimalsErbB ReceptorsHumansInterleukin-6MiceQuality of LifeErbB ReceptorsInterleukin-6PPAR gammaanti-EGFR therapycancer biologycell biologycutaneous toxicitydermal adipose tissuePPARγrat

Identifiers

PMID35324426
PMCPMC8947768
OpenAlexW4226266897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.